Table 3.

Predictors associated with treatment response

Variable	Treatment Response: Logistic Regression
	Odds Ratio (95% CI)	P Value
Univariate model
Age, quartiles
54–64 yr (versus <54 yr)	0.73 (0.29 to 1.82)	0.50
65–74 yr (versus <54 yr)	0.80 (0.33 to 1.97)	0.63
≥75 yr (versus <54 yr)	0.47 (0.18 to 1.22)	0.12
MPO-ANCA (versus PR3)	0.40 (0.21 to 0.79)	0.01
eGFR>10 ml/min per 1.73 m2 (versus ≤10)	3.16 (1.30 to 7.70)	0.01
Cyclophosphamide (versus glucocorticoids)	7.28 (2.03 to 26.09)	0.003
Lung involvement (versus none	0.85 (0.41 to 1.64)	0.62
Plasmapheresis (versus no use)	1.26 (0.61 to 2.58)	0.53
Normal glomeruli>10% (versus ≤ 10%)	2.18 (1.13 to 4.22)	0.02
Arteriosclerosis (versus none)	0.25 (0.08 to 0.81)	0.02
Activity index score (unit decrease)	1.07 (0.97 to 1.19)	0.18
Chronicity index score (unit decrease)	1.18 (1.07 to 1.31)	0.002
EUVAS classification (13)
Focal class (versus sclerotic class)	7.00 (1.22 to 40.0)	0.03
Mixed class (versus sclerotic class)	2.63 (1.00 to 6.9)	0.05
Crescentic class (versus sclerotic class)	2.06 (0.84 to 5.08)	0.12
Multivariate modela
Chronicity index score (unit decrease)	1.16 (1.04 to 1.30)	0.02
eGFR>10% (versus ≤10%)	2.77 (1.09 to 7.01)	0.04
Cyclophosphamide use (versus steroids)	4.38 (1.17 to 16.42)	0.03

Activity index score ranges from 0 to 20; chronicity index score ranges from 0 to 16. 95% CI, 95% confidence interval; MPO, myeloperoxidase; PR3, proteinase 3; EUVAS, European Vasculitis Study Group.

^aConcordance statistic=0.73.